



October 15, 2020

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),

**Subject: Launch of Acalabrutinib 100mg capsules (Calquence®)**

We refer to our earlier communication dated March 12, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (**Calquence®**).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch **Calquence®** in India on October 21, 2020.

Acalabrutinib 100mg capsules (**Calquence®**) is:

- indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

We request you to kindly take the above same on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

**Pratap Rudra**  
**Company Secretary & Legal Counsel**

CORPORATE & REGD. OFFICE  
AstraZeneca Pharma India Ltd.  
P. B. No. 4525, Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000  
FAX : +91 80 6774 8857  
CIN : L24231KA1979PLC003563  
WEB : [www.astrazeneca.com/india](http://www.astrazeneca.com/india)

FACTORY  
12th Mile on Bellary Road  
Venkatata, Kattigenahalli Village  
Yelahanka  
Bangalore - 560 063  
INDIA

TEL : +91 80 6774 9000  
FAX : +91 80 2846 2208  
+91 80 6774 9628